TEMPE, A.Z. and FARGO, N.D., Dec. 03, 2019 (GLOBE NEWSWIRE) — Prevention of cancer onset is the ultimate aspiration for animals and humans. Cancer is caused by mutations that are specific to the tumor which continues to mutate — making it extremely...
BRISBANE, Australia, Dec. 3, 2019 /PRNewswire/ — QBiotics Group Limited (QGL), a life sciences company developing novel anticancer and wound healing pharmaceuticals, today announced that it has dosed its first patient in a Phase I/II clinical trial evaluating...
Companies to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer Seattle Genetics, Inc. and Astellas Pharma Inc.have announced a clinical collaboration agreement with Merck, known as MSD outside the...
No evidence of cardiotoxicity to date; 40% of 10 patients dosed at ≥120 mg/m² demonstrate efficacy; trial progresses in Europe to 210 mg/m² HOUSTON, Dec. 4, 2019 /PRNewswire/ — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the...
Baseline-matched Real-World external Control Data with Alzheimer’s Disease Neuroimaging Initiative (ADNI): ANAVEX®2-73 (blarcamesine) Cohort showed a Significantly lower Cognitive Decline Compared to the ADNI Control Cohort at Interim 2-Year (104-Week) Timepoint...
ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced the recent achievement of two significant clinical trial milestones, enrollment of 60...
Email
Text